GlassScriptPhysician profile
Michelle Talag
NPI 1114319738
$6,135.71
in general payments reported to CMS, 2019-2025
45 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $808 · 2022: $646 · 2023: $1,278 · 2024: $1,680 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,681.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,071.10 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $597.40 | 2021-2025 | |
| Lilly USA, LLC | $462.24 | 2022-2025 | Mounjaro, Zepbound, Reyvow |
| Pfizer INC. | $338.85 | 2021-2025 | |
| Amgen INC. | $310.41 | 2021-2025 | Repatha, Otezla, Otezla |
| Mallinckrodt Hospital Products INC. | $306.45 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.19 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $239.96 | 2023-2025 | Breztri, Fasenra, Tezspire |
| Lundbeck LLC | $217.00 | 2022-2025 | Vyepti |
| Eisai INC. | $202.88 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $194.57 | 2022-2025 | |
| Exact Sciences Corporation | $176.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Jazz Pharmaceuticals INC. | $169.92 | 2021 | |
| Merck Sharp & Dohme LLC | $137.38 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Ucb, INC. | $131.49 | 2023-2025 | Rystiggo, Briviact, Fintepla |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $101.41 | 2024-2025 | |
| Glaxosmithkline, LLC. | $92.99 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $87.12 | 2022-2025 | Keveyis, Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $83.63 | 2023-2025 | |
| Verona Pharma, INC. | $79.24 | 2025 | Ohtuvayre |
| Tandem Diabetes Care, INC. | $71.40 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $70.39 | 2023-2025 | Strensiq |
| Insulet Corporation | $56.03 | 2021-2024 | Omnipod |
| Baxter Healthcare | $55.47 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Radius Health, INC. | $52.52 | 2024-2025 | Tymlos |
| Corcept Therapeutics | $46.64 | 2022-2023 | Korlym |
| Insmed, INC. | $43.67 | 2022-2023 | Arikayce |
| Neurelis, INC. | $41.41 | 2023-2024 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $38.76 | 2021 | |
| Electromed, INC. | $37.35 | 2024-2025 | Smartvest |
| Biogen, INC. | $35.56 | 2023-2024 | Spinraza, Vumerity, Tysabri |
| Grifols USA, LLC | $34.41 | 2023-2025 | Prolastin-C Liquid, Gamunex-C |
| Dexcom, INC. | $31.77 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $27.41 | 2021-2023 | Glassia |
| Ani Pharmaceuticals, INC. | $25.29 | 2024 | Purified Cortrophin Gel |
| Madrigal Pharmaceuticals | $25.09 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $24.89 | 2025 | Qutenza |
| Phathom Pharmaceuticals, INC. | $23.58 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $21.47 | 2023 | Quviviq |
| Mylan Specialty L.P. | $20.96 | 2022 | |
| Cequr Corporation | $20.23 | 2023 | Cequr Simplicity |
| Medtronic, INC. | $19.71 | 2024 | Minimed 780g |
| Recordati_rare_diseases_inc. | $19.04 | 2024 | Signifor Lar, Isturisa |
| Optinose US, INC. | $13.68 | 2024 | |
| Harmony Biosciences LLC | $13.30 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Talag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.